BDA-366: has antineoplastic activity; binds Bcl-2 protein; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
BDA-366 : A member of the class of anthraquinone that is 1,4-diamino-9,10-anthraquinone in which the two amino groups are carrying 3-(diethylamino)-2-hydroxypropyl and (oxiran-2-yl)methyl substituents. It exhibits anti-cancer properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 91826545 |
| CHEMBL ID | 5201080 |
| CHEBI ID | 86325 |
| SCHEMBL ID | 20152431 |
| Synonym |
|---|
| 1-{[(2s)-3-(diethylamino)-2-hydroxypropyl]amino}-4-({[(2s)-oxiran-2-yl]methyl}amino)anthracene-9,10-dione |
| CHEBI:86325 |
| bda-366 |
| CHEMBL5201080 , |
| 142645-19-0 |
| AKOS030632023 |
| DC9709 |
| Q27159082 |
| S7849 |
| 1909226-00-1 |
| bda-366 (1821496-27-8) |
| EX-A2362 |
| bda 366 |
| bda366 |
| 9,10-anthracenedione, 1-[[(2s)-3-(diethylamino)-2-hydroxypropyl]amino]-4-[[(2s)-2-oxiranylmethyl]amino]- |
| SCHEMBL20152431 |
| BCP25061 |
| bda 366; bda366;1909226-00-1 |
| bda 366; bda366 |
| BCP17018 |
| 1-[[(2s)-3-(diethylamino)-2-hydroxypropyl]amino]-4-[[(2s)-oxiran-2-yl]methylamino]anthracene-9,10-dione |
| CCG-268924 |
| bdbm50590324 |
| CS-0020795 |
| HY-101083 |
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| anthraquinone | |
| epoxide | Any cyclic ether in which the oxygen atom forms part of a 3-membered ring. |
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Ki | 0.0033 | 0.0000 | 0.1901 | 2.9000 | AID1853855 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Ki | 0.5000 | 0.0000 | 0.4581 | 9.0000 | AID1853856 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | Ki | 0.5500 | 0.0010 | 1.4653 | 9.5400 | AID1853857 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1853856 | Binding affinity to human Bcl-xL assessed as inhibition constant incubated for 15 mins by competition fluorescence polarization assay | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1853855 | Binding affinity to human Bcl-2 assessed as inhibition constant incubated for 15 mins by competition fluorescence polarization assay | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1853857 | Binding affinity to human Mcl-1 assessed as inhibition constant incubated for 15 mins by competition fluorescence polarization assay | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.80) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (28.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||